WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017177230) METHODS FOR TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/177230 International Application No.: PCT/US2017/026819
Publication Date: 12.10.2017 International Filing Date: 10.04.2017
IPC:
C07K 16/28 (2006.01) ,A61K 39/395 (2006.01) ,A61K 45/06 (2006.01)
Applicants: X4 PHARMACEUTICALS, INC.[US/US]; 784 Memorial Drive Suite 140 Cambridge, Massachusetts 02139, US
Inventors: ARBEIT, Robert, D.; US
Agent: REID, Andrea L.C.; US
ARICO, Joseph W.; US
FLEMING, Paul R.; US
SCALTRITO, Donald V.; US
DECHERT LLP; One International Place, 40th Floor 100 Oliver Street Boston, Massachusetts 02110-2605, US
Priority Data:
62/319,85708.04.2016US
Title (EN) METHODS FOR TREATING CANCER
(FR) MÉTHODES DE TRAITEMENT DU CANCER
Abstract:
(EN) The present invention relates to methods of treating patients with advanced forms of cancer, such as unresectable or metastatic renal cell carcinoma or kidney cancer, in which X4P-001 or a pharmaceutically acceptable salt thereof is administered as monotherapy or in combination with an immune checkpoint inhibitor, such as nivolumab. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.
(FR) La présente invention concerne des méthodes de traitement de patients présentant des formes avancées de cancer, telles qu'un carcinome à cellules rénales non résécable ou métastatique ou un cancer du rein, dans lesquelles du X4P-001 ou un sel pharmaceutiquement acceptable de celui-ci est administré en tant que monothérapie ou en combinaison avec un inhibiteur de point de contrôle immunitaire, tel que le nivolumab. Ces méthodes montrent des résultats surprenants, notamment la régression de la maladie, avec comparativement peu de toxicité.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)